Literature DB >> 1328895

Electrophysiologic and inotropic effects of alpha-adrenoceptor stimulation in human isolated atrial heart muscle.

U Jahnel1, H Jakob, H Nawrath.   

Abstract

The effects of alpha-adrenoceptor stimulation on force of contraction were investigated in human atrial heart muscle and compared with those of beta-adrenoceptor stimulation. The maximal positive inotropic effect produced by stimulation of alpha-adrenoceptors with phenylephrine (in the presence of atenolol 10 mumol/l) was significantly smaller than that seen in response to beta-adrenoceptor stimulation with isoprenaline. The maximal effect of phenylephrine (25% of the maximal effect of isoprenaline) required far higher concentrations (1 mmol/l) than isoprenaline (100 nmol/l); the EC50 values amounted to 33.1 mumol/l and 3.3 nmol/l, respectively. In the presence of the alpha-adrenoceptor blocking agent phentolamine (1 mumol/l), the concentration-response curve of phenylephrine was displaced to higher concentrations of the agonist; under these conditions, the EC50 value amounted to 52.5 mumol/l. The effects of the catecholamines noradrenaline and adrenaline on force of contraction remained unchanged in the presence of phentolamine (1 mumol/l) or prazosin (1 mumol/l). The positive inotropic effect of phenylephrine (1 mmol/l) was associated with a slight decrease in action potential duration; the effects on action potential were completely blocked in the presence of phentolamine (1 mumol/l). These findings support the view that selective stimulation of alpha-adrenoceptors may mediate a small but detectable positive inotropic effect in human atrial tissue under in vitro conditions. The requirement of high concentrations of alpha-adrenoceptor agonists and the lack of effects of the endogenous catecholamines adrenaline and noradrenaline on alpha-adrenoceptors (in concentrations which fully elicit the beta-adrenoceptors-mediated response) do not provide a basis for a functional role of alpha-adrenoceptor-mediated effects under in vivo conditions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328895     DOI: 10.1007/bf00167575

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  22 in total

1.  Adrenoceptors in myocardial regulation: concomitant contribution from both alpha- and beta-adrenoceptor stimulation to the inotropic response.

Authors:  J B Osnes; H Aass; T Skomedal
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 2.  Existence and functional role of alpha 1-adrenoceptors in the mammalian heart.

Authors:  R Brückner; A Mügge; H Scholz
Journal:  J Mol Cell Cardiol       Date:  1985-07       Impact factor: 5.000

3.  Stimulation by adrenaline and dopamine but not by noradrenaline of myocardial alpha-adrenoceptors mediating positive inotropic effects in human atrial preparations.

Authors:  J Wagner; H J Schümann; A Knorr; N Rohm; J C Reidemeister
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

Review 4.  Adrenoceptor-mediated changes of excitation and contraction in isolated heart muscle preparations.

Authors:  H Nawrath
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

5.  Time course and extent of alpha 1-adrenoceptor density changes in rat heart after beta-adrenoceptor blockade.

Authors:  V Steinkraus; M Nose; H Scholz; K Thormählen
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

6.  Depolarization-induced influx of sodium in response to phenylephrine in rat atrial heart muscle.

Authors:  U Jahnel; H Nawrath; E Carmeliet; J Vereecke
Journal:  J Physiol       Date:  1991-01       Impact factor: 5.182

7.  Functional alpha-adrenoceptors in human atrial preparations in the presence of beta-receptor blockade.

Authors:  J A Ask; G Stene-Larsen; K B Helle; F Resch
Journal:  Acta Physiol Scand       Date:  1987-11

8.  Differential electrophysiologic and inotropic effects of phenylephrine in atrial and ventricular heart muscle preparations from rats.

Authors:  R Ertl; U Jahnel; H Nawrath; E Carmeliet; J Vereecke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

9.  Relationship between beta-adrenoceptors and calcium channels in human ventricular myocardium.

Authors:  D R Ferry; A J Kaumann
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

10.  Functional role of cholinoceptors and purinoceptors in human isolated atrial and ventricular heart muscle.

Authors:  H Jakob; H Oelert; J Rupp; H Nawrath
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

View more
  6 in total

Review 1.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

2.  Modulation of the inwardly rectifying K+ channel in isolated human atrial myocytes by alpha 1-adrenergic stimulation.

Authors:  R Sato; S Koumi
Journal:  J Membr Biol       Date:  1995-11       Impact factor: 1.843

3.  Phenylephrine acts via IP3-dependent intracellular NO release to stimulate L-type Ca2+ current in cat atrial myocytes.

Authors:  Y G Wang; E N Dedkova; X Ji; L A Blatter; S L Lipsius
Journal:  J Physiol       Date:  2005-06-09       Impact factor: 5.182

4.  Diverse inotropic effects of 5-hydroxytryptamine in heart muscles of various mammalian species.

Authors:  H Zaizen; S Imanishi; M Nasu; M Arita
Journal:  Heart Vessels       Date:  1996       Impact factor: 2.037

5.  alpha-Adrenergic inhibition of the beta-adrenoceptor-dependent chloride current in guinea-pig ventricular myocytes.

Authors:  I Iyadomi; K Hirahara; T Ehara
Journal:  J Physiol       Date:  1995-11-15       Impact factor: 5.182

6.  Propranolol unmasks class III like electrophysiological properties of norepinephrine.

Authors:  S Dhein; R Gerwin; U Ziskoven; M Schott; A F Rump; Y Zhao; A Salameh; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.